Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...

Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as ...

Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...

H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...

Ventyx’s relationship with Sanofi may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties in ...

The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...

Sanofi's (SNY) plans to seperate its consumer care unit draws buyout bids with over €10B in funding committed from banks and ...

Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...